References in periodicals archive ?
Empliciti was initially approved by the FDA in 2015 in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.
The American Cancer Society has more on multiple myeloma.
"REVLIMID-based regimens are often used as a standard of care in newly diagnosed multiple myeloma patients, and there is a growing patient population who become refractory to REVLIMID and need proven treatment options."
Total 80 participants with newly diagnosed multiple myeloma as per inclusion criteria were included.
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia.
"IL-18 is critical in the progression of multiple myeloma by enabling one part of the immune system to suppress another."
Alimentary symptoms of multiple myeloma include malabsorption, constipation, diarrhea, abdominal pain, motility disturbance, perforation, obstruction, intestinal infarction, and hemorrhage (8-12).
Additional regulatory applications for XGEVA for the prevention of skeletal-related events in patients with multiple myeloma are underway and have been submitted to health authorities worldwide.
The last decade has observed rapid growth of knowledge pertaining to genomic and molecular characterization of multiple myeloma which was made possible due to technological advancements.
Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease.
BioInvent International has been granted additional patent protection in Japan, Russia and China for BI-505, its lead immune-oncology programme currently in Phase II for the treatment of multiple myeloma. These patents cover the use of BI-505 in the treatment of patients previously treated for cancer that have either not responded or subsequently relapsed.

Full browser ?